#United States #AI Solutions #San Francisco #J.P. Morgan #EDETEK

EDETEK to Present at the 44th Annual J.P. Morgan Healthcare Conference

EDETEK Inc., a pioneering force in digital clinical platforms and AI-driven solutions, is set to make a significant impact at the upcoming 44th Annual J.P. Morgan Healthcare Conference. Scheduled for January 14, 2026, at the Westin St. Francis in San Francisco, the presentation will be led by Jian Chen, the company's CEO, alongside Dr. Shakthi Kumar, Chief Strategy and Business Officer.

During this highly anticipated session, EDETEK will unveil its strategic plans and innovations that are redefining clinical development processes. Key elements of their presentation will include insights into the RD Cloud Ecosystem, revolutionary therapeutic accelerators like ONCO+, BioStat.AI, Agentic AI, and a suite of AI solutions designed to streamline various clinical operations.

Commitment to Innovation

Jian Chen emphasized EDETEK's dedication to fostering advancements that not only enhance clinical development but also improve quality. He stated, "EDETEK is committed to driving innovation that accelerates clinical development and improves quality. Our platforms deliver measurable impact for sponsors and CROs by reducing complexity and enabling smarter, faster decisions."

Dr. Kumar further explained the company's vision, stating that they are developing solutions aimed at transforming clinical operations. He highlighted the importance of creating sustainable value for a wide range of stakeholders, including patients, sponsors, CROs, and investors. In his words, "EDETEK's AI-powered platforms simplify complexity, speed timelines, enhance regulatory compliance, and support data-driven decisions that improve outcomes and efficiency."

The Significance of AI in Clinical Research

The global clinical trials market is expected to surpass $80 billion by 2030, fueled by the growing intricacies associated with drug development, stringent regulatory requirements, and the demand for faster results. Notably, the adoption of AI in clinical research is on a rapid rise, with projections indicating that up to 50% of trial processes could be automated via AI by 2030. EDETEK's technological solutions uniquely position the company to lead this transformation, offering scalable tools that minimize development timelines, enhance compliance, and unlock substantial cost efficiencies for both sponsors and clinical research organizations (CROs).

Access to Webcast and Replay

Following the event, EDETEK will entertain requests for webcasts and replays through its official website for a limited period. Interested parties looking to schedule meetings during the conference can visit www.edetek.com for further details.

About EDETEK

Founded in 2009, EDETEK has emerged as a leader in providing AI-powered platforms and clinical services to pharmaceutical, biotechnology, and medical device companies around the globe. With a strong focus on innovation, interoperability, and quality within clinical development, EDETEK currently serves more than 120 biopharma clients across four continents. Their platforms and services have been instrumental in supporting over 50 successful regulatory filings, underscoring EDETEK’s role as a vital player in the clinical innovation landscape.

Conclusion

As EDETEK prepares to present at the J.P. Morgan Healthcare Conference, the industry is keenly awaiting insights into how the latest advancements in AI can further revolutionize clinical research, ultimately leading to better healthcare outcomes and faster drug development. With a clear strategic roadmap and innovative solutions tailored for the evolving demands of clinical trials, EDETEK continues to position itself as a leader in the digital and AI-driven transformation of healthcare.